San Diego-primarily based Viking Therapeutics marked alone as a serious competitor in the weight loss drug current market in February soon after revealing promising data from the mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented as a weekly injection As well as in March t